Securing the best price for an out-licensed asset

Ensysce Biosciences, a biotech focused on combating prescription drug abuse, needed comprehensive data on deals, drugs, companies and patents to identify the best partnership and pricing terms while out-licensing its proprietary abuse/overdose-resistant prodrug technology. It used Clarivate's Cortellis Deals Intelligence together with Cortellis Competitive Intelligence, consolidating the relevant information into a single platform. This let Ensysce make more informed decisions when pursuing global out-licensing and partnering opportunities. The page does not state a specific dollar figure or final deal outcome.

Clarivate owns Cortellis, the curated competitive-intelligence and pipeline-tracking platform standard in pharma portfolio-management teams.

This sits in the Data Providers stage of the AI use-case lifecycle: Named examples from the real-world-data, claims and competitive-intelligence providers pharma AI systems are trained on, benchmarked against, or run inside of.